AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01559090
Drug: MEDI-546
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stage I: 1000 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 1000 mg IV, multiple doses once every 4 wks for 156 wks, the dose at Stage II was changed to 300 mg IV.
Trial: NCT01719133
Drug: AllerT5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: synthetic peptide T5
Trial: NCT01719133
Drug: mix of AllerT1-T2-T3
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mix of peptides T1, T2 and T3
Trial: NCT01719133
Drug: mix of AllerT4-T5
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mix T4-T5
Trial: NCT04370977
Drug: Coartem™ (Artemether-lumefantrine combination)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL (Coartem™) was administered twice daily for three days (six doses in total) with dosage determined according to body weight: one tablet (20mg artemether and 120mg lumefantrine) for children 5 to \<15kg, two tablets per dose for those 15 to \<25kg, and three tablets per dose for those 25 to \<35kg.
Trial: NCT02723877
Drug: PQR309
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual phosphatidylinositol 3-kinase phosphoinositide 3-kinase/ mammalian target of rapamycin Inhibitor (= PI3K/mTOR Inhibitor)
Trial: NCT00655863
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.
Trial: NCT00300196
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mL/kg/hr
Trial: NCT02014272
Drug: reference drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will receive a single oral dose of 4 x 150 mg rifampicin capsules and 3 x 100 mg isoniazid capsules.
Trial: NCT04141163
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No therapeutic effect
Trial: NCT01060462
Drug: Pts. w/ neutropenic fever associated w/ hematologic malignancy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 200 mg twice daily for 2 days for a total of 4 doses, then 200 mg once daily for 12 days. After 14 days of IV administration, itraconazole oral solution 200 mg twice daily should be continued for a total of 14 days until clinically significant resolution of neutropenia resolves
Trial: NCT04400318
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection subcutaneous
Trial: NCT00616161
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03636256
Drug: NanoDoce (direct injection)
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive NanoDoce injected into the index tumor resection site on the bladder wall, immediately following transurethral resection of the bladder tumor (TURBT)
Trial: NCT00445692
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given Orally (PO)
Trial: NCT03636256
Drug: NanoDoce (intravesical instillation) - Visit 2 Instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will receive an initial intravesical instillation within 2 hours of direct injection.
Trial: NCT03636256
Drug: NanoDoce (intravesical instillation) - Induction and Maintenance Instillations
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 (NMIBC) will receive intravesical instillations in an Induction Period and a Maintenance Period.
Trial: NCT00171275
Drug: Fluvastatin
RxNorm normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03766594
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid(R) 0.5mg tablets once daily for 3 months preconceptionally
Trial: NCT03766594
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet apparently identical to Respatio(R) 25mg tablets, taken four times daily for 24 days preconceptionally starting first day of previous period
Trial: NCT04688021
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1.8 g/m2/day administered IV day -5 through -4.
Trial: NCT03173339
Drug: High remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil was started as 0.25 mcg/kg/min. Remifentanil dose was adjusted to maintain blood pressure (20% of preoperative blood pressure) and bispectral index (40-60) by 0.05 mcg/kg/min.
Trial: NCT03173339
Drug: Low remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil was administered as 0.1 mcg/kg/min.
Trial: NCT00599001
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02517619
Drug: Prednisolone Acetate Ophthalmic (1%)
RxNorm normalized name: prednisolone acetate Ophthalmic Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone Acetate (1%)
Trial: NCT01655875
Drug: AMD3100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMD3100 will first be administered at 240 mcg/kg (the FDA approved dose for mobilization of autologous PBSC) IV once daily prior to conditioning for 3 days (days -6, -5 and -4) in the first group of participants. If toxicity criteria are met, the dosing will be escalated in the second group of participants to 240 mcg/kg IV once daily prior to conditioning for 5 days (days -8, -7, -6, -5 and -4).
Trial: NCT00885651
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02348333
Drug: FYU-981, (Oral daily dosing for 7 days)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to the FYU-981 arm receive active drug, FYU-981.
Trial: NCT02348333
Drug: Placebo, (Oral daily dosing for 7 days)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to the placebo arm receive placebo.
Trial: NCT00759291
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet orally every 6 hours for 7 days, with a dose at 7 am on the morning of the study visit
Trial: NCT06064448
Drug: Ningmitai capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects took Ningmitai capsule, 0.38 g/capsule, 3 times a day, 4 capsules each time, after meals, and continued to treat for 4 weeks.
Trial: NCT00607035
Drug: Olmesartan medoxomil + Hydrochlorothiazide
RxNorm normalized name: hydrochlorothiazide / olmesartan medoxomil Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The ARB plus Diuretics combination therapy group is administered olmesartan medoxomil 20mg/day and hydrochlorothiazide 12.5mg/day for 6 months.
Trial: NCT00482833
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maintenance therapy 6-Mercaptopurine (6-MP), 50 mg/m2/day orally. The dose will be adjusted according to hematopoietic toxicity during the follow-up period
Trial: NCT00482833
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Maintenance therapy Methotrexate (MTX), 15 mg/m2/weekly intramuscularly. The dose will be adjusted according to toxicity during the follow-up period.
Trial: NCT00879216
Drug: VA106483
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg orally on either Day 7 or 10 with the placebo crossover treatment on the alternate day.
Trial: NCT00879216
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg orally on either Day 7 or 10 with the placebo crossover treatment on the alternate day.
Trial: NCT01958970
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered once weekly by IV infusion.~Cohort dose schedules:~* 3mg/kg weekly for 12 weeks~* 3mg/kg for 3 weeks, followed by 1mg/kg for 9 weeks~* 6mg/kg for 3 weeks, followed by 2mg/kg for 9 weeks
Trial: NCT02469857
Drug: AB103 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01614743
Drug: Bacteriostatic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo at baseline, incobotulinumtoxinA at 16 weeks
Trial: NCT01144832
Drug: placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one capsule once daily
Trial: NCT03601533
Drug: Phenol
RxNorm normalized name: Phenol
DrugBank: Phenol (DB03255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1,5 mL of 7% phenol will be injected in each of genicular nerves (superior, medial and lateral).
Trial: NCT00378521
Drug: MQX-503
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04217590
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days.
Trial: NCT02251288
Drug: MF59 adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novartis supplies the MF59 adjuvant as an oil-in-water milky emulsion in single-use vials containing a fill volume of 0.7 mL. Group 1 through Group 5 will receive MF59 IM on Day 1.
Trial: NCT03243760
Drug: CCI15106 7.5 mg capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orange capsule containing a white to off-white powder, 21.4 mg of CCI15106: Trehalose:Trileucine 35/55/10 weight by weight (w/w)
Trial: NCT03243760
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orange capsule containing a white to off-white powder, 21.4 mg of Trehalose:Trileucine 85/15 w/w
Trial: NCT03243760
Drug: Placebo-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orange capsule containing a white to off-white powder, 21.4 mg of lactose. Placebo-2 to be used if unexpected safety signals are observed with the use of matching placebo.
Trial: NCT01419847
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03185429
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 mg/m2 by vein before the first cell infusion.
Trial: NCT02190838
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: per os 3 mg daily
Trial: NCT00406809
Drug: ABT-263
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution~Phase 1 dosing was under two different schedules: 14 days on drug, 7 days off or 21 days continuous dosing.~Oral solution and tablets~Phase 2a dosing under 21 day continuous dosing.~- 150 mg lead-in dose for 7-14 days followed by a 325 mg continuous once daily dose.
Trial: NCT00952198
Drug: ARRY-403, glucokinase activator; oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple dose, escalating
Trial: NCT00952198
Drug: Placebo; oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT03597308
Drug: 600mg of Ibuprofen every 6 hours as needed for pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600mg of Ibuprofen every 6 hours as needed for pain
Trial: NCT03597308
Drug: 500mg of Acetaminophen every 6 hours as needed for pain
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mg of Acetaminophen every 6 hours as needed for pain
Trial: NCT00701077
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02821312
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A will comprise a single-dose, sequential-group study incorporating a food effect evaluation. Total 70 subjects will be studied in 7 groups (Groups A1 to A7); 60 male and 10 female. Each group will consist of 10 subjects of the same sex and 2 subject for DA-8010.~Part B will comprise a multiple-dose, sequential-group study. Total forty subjects (30 male and 10 female) will be studied in 4 groups (Groups B1 to B4), with each group consisting of 10 subjects of the same sex and 2 subject for DA-8010.
Trial: NCT02091063
Drug: ACY-1215
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will take the oral ACY-1215 160mg for 28 consecutive days on a 28-day treatment cycle. Each dose will be administered at least 1 hour after ingestion of food and followed by at least 4 ounces of water. Patients will be instructed not to ingest food or other oral medication for at least 2 hours after each ACY-1215 dose.
Trial: NCT02373813
Drug: Oral methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: During the open-label run-in period, methotrexate will be provided as 2.5 mg tablets.~During the double-blind treatment period, methotrexate will be provided as 2.5 mg capsules.
Trial: NCT02373813
Drug: Placebo for methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methotrexate placebo capsules
Trial: NCT01387256
Drug: medical abortion
RxNorm normalized name: ABSORPTION BASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pregnancy termination with drugs
Trial: NCT01074619
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg the first week, then 10 mg the second week, 15 mg the third week and finally 20 mg the fourth week until the end of the study (t0 + 1 year)
Trial: NCT00002566
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03443804
Drug: Test(DW1401)
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DW1401+Placebo of Stillen tab.
Trial: NCT02963181
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Monitor the effects of melatonin on supine hypertension in NOH patients with intact and denervated post-ganglionic nerves.~Identify the mechanistic pathway of melatonin in blood pressure regulation
Trial: NCT00405769
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 caps bid
Trial: NCT01450098
Drug: LY2484595 Reference Formulation (RF)
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00561951
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corresponding placebo tablets OD for 12 weeks
Trial: NCT01329965
Drug: LPS (reference endotoxin, E. coli O113:H10:K:neg, manufactured under GMP)
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPS or placebo (saline-salt water) will be injected (at approximately 7:30 am) in this catheter by a trained GCRC staff member involved with this study. Participants will not be told if they have received the drug or placebo. The LPS is a sterile solution of protein-free endotoxin which will be injected at a dose of 0.6 ng/kg body weight. Blood samples will be collected from a venous catheter for the first 12 hours and by venipuncture thereafter. Subjects will be continuously monitored by trained nursing staff for blood pressure (q 15 minutes) and body temperature (q 30 minutes), and the study will have physician oversight.
Trial: NCT00788424
Drug: AS101 Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% AS101 Cream or Placebo cream, twice a day for 12 weeks
Trial: NCT00826280
Drug: overencapsulated caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00826280
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02472353
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard of care treatment with doxorubicin
Trial: NCT04587713
Drug: TD-1473 [Tablet A]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TD-1473 \[Tablet A\] (1 Tablet = Dose A) proposed commercial tablet formulation
Trial: NCT04587713
Drug: TD-1473 [Tablet B]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TD-1473 \[Tablet B\] (2 Tablets = Dose A) current clinical tablet formulation
Trial: NCT02204189
Drug: TongFuSan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TongFuSan 1g
Trial: NCT00431418
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution
Trial: NCT00207740
Drug: CNTO148
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type=exact type, unit=mg, number=50, 75, 100, 150, 200 and 300, form=injection, route=subcutaneous. Every 4 weeks partciapnts will receive injections in 4 parallel treatment arms
Trial: NCT00207740
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type=exact type, unit=mg, form=injection, route=subcutaneous. Placebo will be given from from Week 0 through Week 52.
Trial: NCT00284856
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fluticasone propionate 250 mcg Placebo (Pbo) twice daily, 6 month treatment period
Trial: NCT00284856
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: montelukast 10 mg Pbo tablet once daily, 6 month treatment period
Trial: NCT02357758
Drug: Antibiotic Prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approved clinical dosage or antibiotics
Trial: NCT02499562
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03277573
Drug: Salsalate
RxNorm normalized name: Salsalate
DrugBank: Salsalate (DB01399)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salsalate is a non-acetylated dimer of salicylic acid, and is classified as a non-steroidal anti-inflammatory drug (NSAID). Salsalate has been commercially available in the US as a prescription drug for the relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis, and related rheumatic disorder for decades.
Trial: NCT03277573
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive ingredient
Trial: NCT04667897
Drug: 601 1.25mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection (intravitreal use)
Trial: NCT04667897
Drug: Ranibizuman 0.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection (intravitreal use)
Trial: NCT02061657
Drug: Placebo( for misoprostol)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Include 25 patients undergoing myomectomy operation will not receive misoprostol before the operation.
Trial: NCT01551836
Drug: Paracetamol formulation 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: formulation 1
Trial: NCT01551836
Drug: Paracetamol formulation 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation 2
Trial: NCT01837043
Drug: Calcineurin Inhibitor
RxNorm normalized name: Calcineurin inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02213900
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02730741
Drug: Lcr restituo® sachet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: symptomatic treatment of diarrhoea
Trial: NCT02730741
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00372385
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT00210977
Drug: No intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an observational study. All participants will be maintained on their regular dose regimen of standard-of-care treatment, under the guidance of the treating physician/investigator.
Trial: NCT01777269
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take one capsule daily
Trial: NCT00504881
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 16-week Treatment Period
Trial: NCT02967172
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01605331
Drug: sustained-release recombinant human GH (SR-rhGH)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02275936
Drug: N91115
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S Nitrosoglutathione Reductase Inhibitor
Trial: NCT00695019
Drug: placebo lozenges
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg matching placebo lozenges
Trial: NCT01508000
Drug: FOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU, folinic acid, oxaliplatin
Trial: NCT01822288
Drug: Estradiol & medroxyprogesterone acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol \& medroxyprogesterone acetate once a day for patients with menopausal syndromes, for patients without the need for self-paid drug
Trial: NCT03146390
Drug: Essential oils
RxNorm normalized name: essential oils
FDA approved: no
EMA approved: no
PMDA approved: no
Description: all subjects will perform all interventions of all arms
Trial: NCT03146390
Drug: Alcohol free essential oils
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: all subjects will perform all interventions of all arms
Trial: NCT02658721
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: If the patient had a VAS score of \>4 and if required, 1 μg/kg fentanyl was administered for analgesia and the dosage and time were recorded.
Trial: NCT02658721
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The patients with a VAS score of \>4 were administered with 75 mg diclofenac sodium via intramuscular route.